Joachim Bröeker
Boehringer Ingelheim (Austria)(AT)
Publications by Year
Research Areas
Asymmetric Synthesis and Catalysis, HER2/EGFR in Cancer Research, Chemical Synthesis and Analysis, Colorectal Cancer Treatments and Studies, Peptidase Inhibition and Analysis
Most-Cited Works
- → Discovery of Quinazolines as Histamine H4Receptor Inverse Agonists Using a Scaffold Hopping Approach(2008)88 cited
- → Targeted Synthesis of Complex Spiro[3H‐indole‐3,2′‐pyrrolidin]‐2(1H)‐ones by Intramolecular Cyclization of Azomethine Ylides: Highly Potent MDM2–p53 Inhibitors(2018)28 cited
- → Abstract 1271: In vitro and in vivo characterization of BI 1823911 - a novel KRASG12C selective small molecule inhibitor(2021)22 cited
- → Chiral linker. Part 3: Synthesis and evaluation of aryl substituted m-hydrobenzoins as solid supported open chain chiral auxiliaries for the diastereoselective reduction of α-keto esters(2006)15 cited
- → Abstract 3317: KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harbouring KRASG12V mutations and KRAS wild-type amplifications(2024)13 cited
- → Synthesis of novel chiral hydrobenzoin mono-tert-butyl ethers derived from m-hydrobenzoin and their application as chiral auxiliaries in the diastereoselective reduction of α-keto esters(2005)9 cited
- → Chiral linker 5: scope and limitations of arylsubstituted m-hydrobenzoins as solid supported open chain chiral auxiliaries for diastereoselective syntheses(2009)7 cited
- → Discovery of BI-2493, a Pan-KRAS Inhibitor Showing In Vivo Efficacy(2025)6 cited
- → Abstract 3321: KRASmulti inhibitor BI 3706674, an orally bioavailable, direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRASG12V-driven preclinical models(2024)3 cited
- → Abstract A092: Determinants of sensitivity to BI KRASmulti inhibitor using high-throughput in-vitro drug screens(2023)1 cited